Does a BRCA mutation plus tamoxifen equal hysterectomy?

Gynecologic Oncology

Volumn 104, Issue 1, 2007, Pages 3-4

  Lu, Karen H ^a   Kauff, Noah D ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HORMONE; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; EDITORIAL; ENDOMETRIUM CANCER; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; RISK REDUCTION; SALPINGOOOPHORECTOMY; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, HORMONAL; COCARCINOGENESIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; HYSTERECTOMY; OVARIECTOMY; TAMOXIFEN; UTERINE NEOPLASMS;

EID: 33846015875     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.11.015     Document Type: Editorial

References (16)

1. Antoniou A., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72 5 (2003) 1117-1130
2. King M.C., Marks J.H., and Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 5645 (2003) 643-646
3. Kauff N.D., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346 21 (2002) 1609-1615
4. Rebbeck T.R., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346 21 (2002) 1616-1622
5. Schmeler K.M., et al. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet. Gynecol. 108 3 (2006) 515-520
6. Meijers-Heijboer E.J., et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355 9220 (2000) 2015-2020
7. Thompson D., and Easton D.F. Cancer incidence in BRCA1 mutation carriers. J. Natl. Cancer Inst. 94 18 (2002) 1358-1365
8. Levine D.A., et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol. Oncol. 80 3 (2001) 395-398
9. Lavie O., et al. BRCA2 germline mutation in a woman with uterine serous papillary carcinoma-Case report. Gynecol. Oncol. 99 2 (2005) 486-488
10. Lavie O., et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol. Oncol. 92 2 (2004) 521-524
11. Goshen R., et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?. Gynecol. Oncol. 79 3 (2000) 477-481
12. Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, et al., and the Hereditary Ovarian Cancer Clinical Study Group. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations: a prospective study. Gynecol. Oncol.
13. Cuzick J., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 9354 (2003) 296-300
14. Rebbeck T.R., et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol. 23 31 (2005) 7804-7810
15. Rossouw J.E., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
16. Society of Gynecologic Oncologists. Clinical practice committee statement on prophylactic salpingo-oophorectomy. Gynecol. Oncol. 98 2 (2005) 179-181